Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products
Executive Summary
The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.
You may also be interested in...
Pharma Merger Divestitures: Some Buyers Fail To Replace Generic Products
US FTC analysis of merger remedy orders finds that of 42 on-market generic products that required manufacturing transfer, the buyer was unable to continue to sell 15 products.
Pharma Merger Divestitures: Some Buyers Fail To Replace Generic Products
US FTC analysis of merger remedy orders finds that of 42 on-market generic products that required manufacturing transfer, the buyer was unable to continue to sell 15 products.
Mylan/Agila Merger Requires Fourth Largest Divestiture In Generic Industry
FTC mandates that the two companies sell off 11 generic injectable drugs as a condition for allowing their merger; Intas, Sagent, JHP Pharmaceuticals and Gland Pharma are to acquire the products.